Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

738.21 -50.88 (-6.45%)
Official Closing Price Updated: 7:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
Eli Lilly stock and Novo Nordisk kicked off the vanity trade, but the "me-conomy" trend is extending to other industries as well. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years
Via Benzinga
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
Investing based on the segment's long-term prospects is likely to be very lucrative. 
Via The Motley Fool
3 Stocks on the Rise After Stellar Q2 Earnings Results
These three companies are earnings winners with impressive revenue and profit numbers. They will continue to shine throughout 2024. 
Via InvestorPlace
VOO Vs. VTI: Here Are The Key Differences Between Vanguard US Stock Market ETFs Investors Should Know
A look at the differences and past performance of the VOO and VTI ETFs and how they compare to the SPY ETF. 
Via Benzinga
Topics ETFs
Beyond The Numbers: 25 Analysts Discuss Eli Lilly Stock
Via Benzinga
Analyzing Eli Lilly In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
A company's investments can easily ruin the plans of its competitors. 
Via The Motley Fool
Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run
Many more quarters like Lilly's stellar second quarter could be on the way. 
Via The Motley Fool
Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
GLP-1 agonists like Ozempic and Wegovy, known for treating obesity and diabetes, are now showing potential in reducing cancer risk, particularly for cancers linked to obesity. New research highlights... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
There isn't much to suggest these businesses are actually vulnerable. 
Via The Motley Fool
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Eli Lilly: A Pharmaceutical Juggernaut That Just Crushed Earnings Estimates
Many have said that pharmaceutical companies would be a logical place to invest if the rest of the market began to slow down. They may have been onto something. Eli Lilly & Co. reported Q2 earnings and... 
Via Talk Markets
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses. 
Via The Motley Fool
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
3 Stocks to Load-Up On Before Autumn Arrives
Consider these stocks to buy before autumn as each has delivered strong financial results and seen their share price rise as a result. 
Via InvestorPlace
Lilly Stock Surging On Healthy Profits: Check Out Who's On The IBD 50, Other Premium Lists
Lilly last week reported an 86% surge in earnings to $3.92 a share, easily beating estimates, as revenue popped 35% to $11.3 billion. 
Via Investor's Business Daily
S&P 500 Erases Weekly Losses, Nasdaq 100 Ends 4-Week Slide As Bulls Regain Momentum: Friday's Stock Movers At The Close
Market indexes rose on Friday, wiping out weekly losses and easing economic fears. Positive catalysts calmed volatility and reassured investors. 
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Eli Lilly's Q2 revenue soared to $11.3 billion, surpassing forecasts. Mounjaro sales tripled and Zepbound revenue grew significantly post-FDA approval. Analysts are cautious about future supply and... 
Via Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
3 Healthcare Stocks to Sell in August Before They Crash & Burn
Investors are looking to the healthcare sector for safe harbor. But these are three healthcare stocks to sell in August 2024. 
Via InvestorPlace
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide. 
Via MarketBeat
Topics ETFs
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space. 
Via The Motley Fool
Eli Lilly & Co. Stocks Elliott Wave Technical Analysis - Friday, August 9
Looking for a top in wave {b} of 4 to then complete the overall correction, knowing we could already have a bottom in Minor wave 4 in place. 
Via Talk Markets
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in. 
Via MarketBeat
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.